logo
logo

Epidarex Capital Closes New £102 Million UK Venture Fund to Build Successful Life Science Companies

Jun 22, 2020•about 5 years ago

Amount Raised

£102 Million

Edinburgh

Description

Epidarex Capital ("Epidarex"), a transatlantic life science venture firm, announces that it has closed Epidarex Capital III UK LP (the "Fund") at £102.1 million. The Fund will build new life science companies based on world-class research and innovation from emerging hubs across the UK, including spinouts from highly regarded universities. Typical initial investments will range from £2 million to £5 million.

Company Information

Company

Epidarex Capital

Location

Edinburgh, Scotland, United Kingdom

About

Epidarex Capital is a transatlantic venture firm that invests in early-stage, high-growth life science companies in under-ventured markets. Epidarex focuses on providing risk capital and expertise to create, support and build young companies, including spinouts, from leading research institutions in both established and emerging life science hubs. The fund's international management team has a track record of successfully partnering with top scientists and entrepreneurs to develop highly innovative products for the global healthcare market.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People